135
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting

, , , , , & ORCID Icon show all
Pages 321-326 | Received 21 Jan 2024, Accepted 02 May 2024, Published online: 08 May 2024
 

ABSTRACT

Introduction

At the 65th American Society of Hematology (ASH) 2023 Annual Meeting, the latest advancements in CD20×CD3 BsAbs for B-cell lymphoma (BCL) were highlighted, particularly in relapsed/refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL).

Areas covered

This summary highlights some of the major studies on CD20×CD3 BsAbs for BCL.

Expert Opinion/Commentary

CD20×CD3 is the most widely studied BsAb, with promising results in patients with R/R DLBCL and R/R FL ≥ two prior lines of systemic therapy. Trials with the first line of B-cell lymphoma also revealed promising results. Hopefully, BsAb monotherapy or BsAb-containing regimens may become the standard therapy in patients with FL and DLBCL.

Abbreviations

ASH=

American Society of Hematology

BCL=

B-cell lymphoma

BsAbs=

bispecific antibodies

CAR T-cell=

chimeric antigen receptor T-cell

CMR=

complete metabolic response

CR=

complete response

CRS=

cytokine release syndrome

DLBCL=

diffuse large B cell lymphoma

FL=

follicular lymphoma

LBCL=

large B-cell lymphoma

ORR=

overall response rate

OS=

overall survival

R/R=

relapsed or refractory

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contribution statement

J Yu designed and directed the manuscript. H Sun, H Xing and L Han wrote the manuscript draft. Y Liu and J Yu revised the manuscript. Y Song and Z Jiang provided resources. All authors reviewed and approved the final manuscript.

Acknowledgments

The authors would like to thank all the patients and their families for participating in clinical trials testing the drugs mentioned in this review.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This paper was funded by the Zhengzhou Municipal Science and Technology Bureau project number XTCX2023010, and Talent Research Fund of the First Affiliated Hospital of Zhengzhou University, granted to J Yu, the National Nature Science Foundation of China [grant number 82270225 granted to L Han].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.